An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam Plus Vancomycin, Linezolid Versus Standard Of Care Plus Vancomycin, Linezolid As Empiric Therapy In Febrile Neutropenic Adults With Cancer
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Ceftazidime/tazobactam (Primary) ; Cefepime; Linezolid; Meropenem; Piperacillin/tazobactam; Vancomycin
- Indications Bacterial infections; Febrile neutropenia
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2019 Planned End Date changed from 31 May 2019 to 31 May 2020.
- 22 Jul 2019 Planned primary completion date changed from 31 May 2019 to 31 May 2020.
- 12 Apr 2019 Planned End Date changed from 1 May 2019 to 31 May 2019.